Results 121 to 130 of about 5,598,449 (384)
Prostate International, 2013 MicroRNAs (miRNAs) are made up of -22 endogenous nucleotides and are small, noncoding RNAs that are important regulators of gene expression at the posttranscriptional level by degrading or repressing target miRNAs. miRNA expression profiles can be used for the detection of diagnostic and prognostic markers for various cancers.
Wun-Jae Kim, Won-Tae Kim
openaire +4 more sources
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
New England Journal of Medicine, 2019 BACKGROUND Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would prolong radiographic progression-free survival and overall survival as compared ...
K. Chi +19 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.Transient receptor potential melastatin‐4 (TRPM4) is overexpressed in prostate cancer (PCa). Knockout of TRPM4 resulted in reduced PCa tumor spheroid size and decreased PCa tumor spheroid outgrowth. In addition, lack of TRPM4 increased cell death in PCa tumor spheroids.
Florian Bochen +6 more
wiley +1 more source
Diagnostics, 2020 Biomarkers for predicting the risk of castration-resistant prostate cancer (CRPC) in men treated with primary androgen deprivation therapy (ADT) are lacking.
Mads Dochedahl Winther +7 more
doaj +1 more source
Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer
Molecular Oncology, EarlyView.mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia +17 more
wiley +1 more source
Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years' follow up [PDF]
, 2012 <b>Background</b> High cholesterol may be a modifiable risk factor for prostate cancer but results have been inconsistent and subject to potential "reverse causality" where undetected disease modifies cholesterol prior to diagnosis.<p ...
A Jemal +48 more
core +2 more sources
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
New England Journal of Medicine, 2014 BACKGROUND The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor.
E. Antonarakis +20 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley +1 more source
Frizzled-8 integrates Wnt-11 and transforming growth factor-β signaling in prostate cancer [PDF]
, 2018 Wnt-11 promotes cancer cell migration and invasion independently of β-catenin but the receptors involved remain unknown. Here, we provide evidence that FZD8 is a major Wnt-11 receptor in prostate cancer that integrates Wnt-11 and TGF-β signals to promote
Carton, J +8 more
core +3 more sources
Divergent clonal evolution of castration resistant neuroendocrine prostate cancer
Nature Network Boston, 2016 An increasingly recognized resistance mechanism to androgen receptor (AR)-directed therapy in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low to absent AR expression and often have neuroendocrine features.
H. Beltran +18 more
semanticscholar +1 more source